Cushing syndrome is caused by long-term exposure to high cortisol levels. Diagnosing the cause can help determine the type of treatment needed. Lifestyle changes can also help with symptoms. Every ...

Recordati Rare Diseases Canada Inc. announced today the Canadian product availability of ISTURISA® (osilodrostat) for the treatment of adult patients with Cushing's disease who have persistent or ...

Expert Rev Endocrinol Metab. 2013;8(2):183-193. Mitotane reduces cortisol synthesis through the inhibition of 11B-hydroxylase, 18-hydroxylase, 3-α hydroxylase, hydroxysteroid dehydrogenase and several ...

The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has ...

ORLANDO, Florida — The investigational drug osilodrostat (Novartis) is showing promise for the treatment of Cushing's disease. Osilodrostat is an orally active inhibitor of 11ß-hydroxylase, the enzyme ...

Please provide your email address to receive an email when new articles are posted on . Adults with Cushing’s syndrome had declines in BP and glucose with relacorilant therapy in the GRACE trial.

Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

A Prescription Drug User Fee Act target date of December 30, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...